Search research articles
Contact Us
Filters
Showing results (131-140 of 232) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
Dai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Nature Medicine
|
August 20, 2013
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
Kyrre E Emblem, Kim Mouridsen, Atle Bjornerud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432
Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.
Seminars in Oncology
|
October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
James H Doroshow, Timothy W Synold, David Gandara, et al.
Frontiers in Medicine
|
June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
Channing J Paller, Erich P Huang, Thomas Luechtefeld, et al.
Investigational New Drugs
|
January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Investigational New Drugs
|
September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Joleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 232) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
Dai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
Elisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Nature Medicine
|
August 20, 2013
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
Kyrre E Emblem, Kim Mouridsen, Atle Bjornerud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2012
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432
Patricia M LoRusso, Karthik Venkatakrishnan, Ramesh K Ramanathan, et al.
Seminars in Oncology
|
October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
James H Doroshow, Timothy W Synold, David Gandara, et al.
Frontiers in Medicine
|
June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials
Channing J Paller, Erich P Huang, Thomas Luechtefeld, et al.
Investigational New Drugs
|
January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
Srikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
Investigational New Drugs
|
September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Joleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, et al.
Page
of 24